Seqens CDMO NA Identifies Key Trends Impacting Industry in 2021 Newburyport, MA, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Seqens CDMO North America (formerly known as PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), active...

Seqens CDMO North America Appoints Jean-Noel David as Managing Director Newburyport, MA & Ecully, FRANCE, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Seqens CDMO North America (formerly known as PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities...

SEQENS inaugurates an innovative HPAPI unit at its century-old active pharmaceutical ingredient production site NEWBURYPORT, MASS., USA & VILLENEUVE-LA-GARENNE, FRANCE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- SEQENS, one of the world leaders in pharmaceutical synthesis and specialty ingredients, inaugurates an...

Seqens CDMO to enhance flow chemistry capabilities at its Seqens'Lab R&D center for efficient and safe synthesis of APIs and intermediates Newburyport, MA & Ecully, FRANCE, June 03, 2020 (GLOBE NEWSWIRE) -- Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical...

SEQENS mobilizes its innovation to support the unprecedented research on the COVID-19 ECULLY, FRANCE & Newburyport, Mass., USA, May 05, 2020 (GLOBE NEWSWIRE) -- Pending the availability of a vaccine, which will necessarily take time, the race against the clock is underway for the...